Rate My Professor Marco Mielcarek

Mielcarek's research centers on preventing and treating graft-versus-host disease (GVHD), a serious complication after allogeneic hematopoietic stem cell transplantation where donor immune cells attack the recipient's tissues. He and colleagues have conducted clinical trials demonstrating that high-dose posttransplantation cyclophosphamide safely prevents GVHD following growth factor-mobilized blood stem cell transplantation. His team showed that lower doses of prednisone effectively treat acute GVHD without compromising outcomes. Key publications include "Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation" (Blood, 2016), "Long-term outcomes after transplantation of HLA-identical related G-CSF–mobilized peripheral blood mononuclear cells versus bone marrow" (Blood, 2011), and studies exploring donor statin treatment to protect against severe acute GVHD. In 2011, he received a $2.2 million grant from the National Institutes of Health's National Heart, Lung, and Blood Institute to advance GVHD research. As Medical Director, Mielcarek oversees efforts to enhance transplant program outcomes, which have been nationally recognized, and integrates cutting-edge clinical trials into patient care to make treatments more tolerable.